氟维司群(Fulvestrant) - 药物靶点：ER_在研适应症：HR阳性乳腺腺癌，乳腺癌，ER阳性乳腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol、Fulvestrant (JAN/USP/INN)、EA-114

+ [15]

靶点

ER

作用方式

拮抗剂

作用机制

ERs拮抗剂(雌激素受体家族拮抗剂)

治疗领域

肿瘤皮肤和肌肉骨骼疾病神经系统疾病+ [5]

在研适应症

HR阳性乳腺腺癌乳腺癌ER阳性乳腺癌+ [31]

非在研适应症

晚期非小细胞肺癌晚期胰腺腺癌复发性乳腺癌+ [22]

原研机构

AstraZeneca PLC

在研机构

Seagen, Inc.

Novartis Pharmaceuticals Corp.

Eli Lilly & Co.

+ [13]

非在研机构

Xynomic Pharmaceuticals, Inc.

Celcuity, Inc.

Genentech, Inc.

+ [2]

权益机构

Zymeworks, Inc.

Boryung Corp.

Pfizer Inc.

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (2002-04-25),

HR阳性乳腺癌

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C32H47F5O3S

InChIKeyVWUXBMIQPBEWFH-WCCTWKNTSA-N

CAS号129453-61-8

关联

475

项与氟维司群相关的临床试验

NCT06849947

/ Not yet recruiting临床2期IIT

Randomized Phase II Trial of Fulvestrant With Ribociclib Versus Physician's Choice Treatments for the Patients Who Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer as First Line Treatment (CLEE011AKR06R)

▪ Fulvestrant With Ribociclib versus Physician's choice treatments for the patients who recurred after completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer as first line treatment

开始日期2025-06-30

申办/合作机构

Samsung Medical Center

NCT06757634

/ Not yet recruiting临床3期

VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

开始日期2025-06-30

申办/合作机构

Celcuity, Inc.

NCT06941142

/ Not yet recruiting临床1期

An Ib/III Study to Evaluate the Safety and Efficacy of Sirolimus（Albumin-bound）in Combination With Palbociclib and Fulvestrant in Patients With Advanced HR- Positive, HER2- Negative Breast Cancer

This study adopts multicenter/randomized trial design. It plans to enroll patients with HR- positive, HER2- negative advanced breast cancer who are resistant to (neo)adjuvant endocrine therapy. Dose-escalation and dose-expansion studies will be carried out to evaluate the safety, tolerability, and preliminary efficacy of sirolimus (albumin-bound) in combination with palbociclib and fulvestrant in this patient population.

开始日期2025-04-30

申办/合作机构

石药集团中奇制药技术（天津）有限公司

100 项与氟维司群相关的临床结果

登录后查看更多信息

100 项与氟维司群相关的转化医学

登录后查看更多信息

100 项与氟维司群相关的专利（医药）

登录后查看更多信息

6,625

项与氟维司群相关的文献（医药）

2025-09-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Surface-enhanced Raman spectroscopy facilitates the detection of multiple metabolic modulators

Article

作者: Yang, Tao ; Li, Yuanyuan ; Ma, Yueyue ; Xia, Zhichao ; Zhou, Na ; Luo, Xiaojun ; Shen, Yushi

Metabolic regulators can improve the athletic ability of athletes by regulating body metabolism, but it is not conducive to fair competition, so it is listed as a prohibited substance. At the same time, the State General Administration of Sport ordered major event organizers to test food for food-borne stimulants. Surface-enhanced Raman scattering (SERS) spectroscopy has been widely used because of its excellent sensitivity and strong spectral characteristics. Based on the available information, SERS spectrum data of metabolic regulators in food-related fields were lacking. In this study, we used gold dodecahedron nanoparticles as SERS active substrate and successfully captured the characteristic peaks of 6 metabolic regulatory factors. A low cost and stable SERS detection technique for detecting trimetazidine in milk samples with good recovery rate was proposed. Therefore, this method can not only protect the food safety of large-scale sports events, but also have broad application prospects in the food field.

2025-08-01·BIOCHEMICAL PHARMACOLOGY

Methyl-oxazolomycin A: A novel oxazolomycin analog with potent selective estrogen receptor degrading activity in breast cancer cells

Article

作者: Oh, Dong-Chan ; Moon, Dong Hyun ; Kim, Seonghun ; Lee, Sang Kook ; Kim, Sanghee ; Park, Jiyoon

Breast cancer (BC), the most prevalent malignancy in women worldwide, is categorized according to the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in tumor cells. Approximately 70% of all BCs are ER-positive and HER2-negative, and estrogen binding to the ER plays a vital role in BC development. We previously reported that methyl-oxazolomycin A, a natural compound isolated from Streptomyces sp. in soil, exhibited selective antiproliferative activity against ER-positive BC cells compared to triple-negative BC cells not expressing ER, PR, and HER2. The present study aimed to elucidate the molecular mechanisms underlying the antiproliferative activity of methyl-oxazolomycin A in two ER-positive BC lines, MCF-7 and T-47D. Methyl-oxazolomycin A effectively reduced the protein levels of ERα via proteasomal degradation while also reducing the protein levels of phosphorylated ERα. Notably, methyl-oxazolomycin A demonstrated potent antiproliferative activity in tamoxifen-resistant MCF-7 cells and downregulated the protein expression of phosphorylated ERα at Tyr537, which SERDs such as fulvestrant fail to target. The antiproliferative activity of methyl-oxazolomycin A was associated with the induction of the G₀/G₁ cell cycle arrest through the modulation of cell cycle checkpoint protein expression. Prolonged treatment with methyl-oxazolomycin A led to an increase in the production of reactive oxygen species and induced apoptosis. These findings, which detail the mechanisms underlying the antiproliferative activity of methyl-oxazolomycin A, support its potential as a novel agent targeting ER-positive BC cells.

2025-06-01·BREAST CANCER RESEARCH AND TREATMENT

FGFR4 in endocrine resistance: overexpression and estrogen regulation without direct causative role

Article

作者: Lee, Adrian V ; Ding, Kai ; Oesterreich, Steffi ; Chen, Lyuqin ; Shah, Osama ; Sikora, Matthew J ; Jankowitz, Rachel ; Tasdemir, Nilgun ; Dabbs, David ; Levine, Kevin M ; Hazan, Rachel ; Atkinson, Jenny

PURPOSE:

Endocrine therapy resistance is the major challenge of managing patients with estrogen receptor positive (ER+) breast cancer. We previously reported frequent overexpression of FGFR4 in endocrine-resistant cell lines and breast cancers that recurred and metastasized following endocrine therapy, suggesting FGFR4 as a potential driver of endocrine resistance. In this study, we investigated the role of FGFR4 in mediating endocrine resistance and explored the therapeutic potential of targeting FGFR4 in advanced breast cancer.

METHODS:

A gene expression signature of FGFR4 activity was examined in ER+breast cancer pre- and post-neoadjuvant endocrine therapy and the association between FGFR4 expression and patient survival was examined. A correlation analysis was used to uncover potential regulators of FGFR4 overexpression. To investigate if FGFR4 is necessary to drive endocrine resistance, we tested response to FGFR4 inhibition in long-term estrogen-deprived (LTED) cells and their paired parental cells. Doxycycline inducible FGFR4 overexpression and knockdown cell models were generated to examine if FGFR4 was sufficient to confer endocrine resistance. Finally, we examined response to FGFR4 monotherapy or combination therapy with fulvestrant in breast cancer cell lines to explore the potential of FGFR4 targeted therapy for advanced breast cancer and assessed the importance of PAM50 subtype in response to FGFR4 inhibition.

RESULTS:

A FGFR4 activity gene signature was significantly upregulated post-neoadjuvant aromatase inhibitor treatment, and high FGFR4 expression predicted poorer survival in patients with ER+breast cancer. Gene expression association analysis using TCGA, METABRIC, and SCAN-B datasets uncovered ER as the most significant gene negatively correlated with FGFR4 expression. ER negatively regulates FGFR4 expression at both the mRNA and protein level across multiple ER+breast cancer cell lines. Despite robust overexpression of FGFR4, LTED cells did not show enhanced responses to FGFR4 inhibition compared to parental cells. Similarly, FGFR4 overexpression and knockdown did not substantially alter response to endocrine treatment in ER+cell lines, nor did FGFR4 and fulvestrant combination treatment show synergistic effects. The HER2-like subtype of breast cancer showed elevated expression of FGFR4 and an increased response to FGFR4 inhibition relative to other breast cancer subtypes.

CONCLUSIONS:

Despite ER-mediated upregulation of FGFR4 post-endocrine therapy, our study does not support a general role of FGFR4 in mediating endocrine resistance in ER+breast cancer. The significant upregulation of FGFR4 expression in treatment-resistant clinical samples and models following endocrine therapy does not necessarily establish a causal link between the gene and treatment response. Our data suggest that specific genomic backgrounds such as HER2 expression may be required for FGFR4 function in breast cancer and should be further explored.

1,293

项与氟维司群相关的新闻（医药）

11 小时之前

·氨基观察

艾伯维c-Met ADC获批；诺华阿思尼布在国内上市

氨基观察-创新药组原创出品作者 | 黄恺水逆王者艾伯维，终于迎来好消息。5月14日，艾伯维宣布，FDA已批准c-Met靶向ADC药物telisotuzumab vedotin上市，用于治疗既往接受过治疗的c-Met蛋白过表达、表皮生长因子受体野生型晚期/转移性非鳞状非小细胞肺癌成人患者。该药物是首款获批上市的c-Met ADC产品。诺华白血病新药再国内获批。5月14日，诺华宣布，阿思尼布片获药监局批准，用于治疗新诊断的费城染色体阳性的慢性髓细胞白血病（Ph+CML）慢性期（CP）成人患者。在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。/ 01 /市场速递1）石药集团就伊立替康脂质体注射液达成授权合作5月15日，石药集团宣布，其已与Cipla公司就伊立替康脂质体注射液于美国的商业化订立独家许可协议。石药集团将收取1500万美元的首付款，亦有权收取最高达2,500万美元的潜在首次商业销售和监管里程碑付款，及最高达10.25亿美元的潜在额外商业销售里程碑付款，以及根据该产品于该地区的年度销售净额计算的双位数梯度销售提成。/ 02 /资本信息1）恒瑞医药已完成回购计划 5月15日，恒瑞医药公告称，本次回购股份事项完成，实际回购公司股份1290.51万股，占公司总股本的比例为0.20%，最高成交价为57.01元/股，最低成交价为39.00元/股，回购均价约为46.59元/股，成交总金额为6.01亿元（不含交易费用）。/ 03 /医药动态1）诺华白血病新药阿思尼布片获批上市5月14日，诺华宣布，阿思尼布片获药监局批准，用于治疗新诊断的费城染色体阳性的慢性髓细胞白血病（Ph+CML）慢性期（CP）成人患者。2）北海康成注射用维拉苷酶β获批上市5月15日，据NMPA官网，北海康成注射用维拉苷酶β获批上市，适用于12岁及以上青少年和成人I型和Ⅲ型戈谢病患者的长期酶替代治疗。公开资料显示，这是一款针对戈谢病开发的酶替代疗法。3）轩竹生物CDK4/6抑制剂获批上市5月15日，据NMPA官网，轩竹生物吡洛西利片获批上市，适用于激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性晚期或转移性乳腺癌成人患者：与氟维司群联合用于既往接受内分泌治疗后出现疾病进展的患者；单药用于既往转移性阶段接受过两种及以上内分泌治疗和一种化疗后出现疾病进展的患者。4）海思科外周kappa阿片受体选择性激动剂获批上市5月15日，据NMPA官网，海思科外周kappa阿片受体选择性激动剂安瑞克芬注射液获批上市，用于治疗腹部手术后的轻、中度疼痛。/ 04 /器械跟踪1）鱼跃医疗自动体外除颤器获得欧盟MDR认证5月15日，鱼跃医疗宣布，自动体外除颤器（AED）产品获得欧盟MDR认证。/ 05 /海外药闻1）艾伯维c-Met ADC获批上市5月14日，艾伯维宣布，FDA已批准c-Met靶向ADC药物telisotuzumab vedotin上市，用于治疗既往接受过治疗的c-Met蛋白过表达、表皮生长因子受体野生型晚期/转移性非鳞状非小细胞肺癌（NSCLC）成人患者。该药物是首款获批上市的c-Met ADC产品。2）诺和诺德加码口服减重小分子药物研发5月14日，诺和诺德宣布与Septerna达成合作，共同开发多款针对G蛋白偶联受体（GPCR）的小分子口服药物。PS：欢迎扫描下方二维码，添加氨基君微信号交流。

上市批准抗体药物偶联物引进/卖出

11 小时之前

·蒲公英Ouryao

NMPA:三款新药获批！

来源：国家药监局编辑：清风2025年05月15日，国家药监局批准了3款新药，分别为注射用维拉苷酶β、吡洛西利片和安瑞克芬注射液。01 注射用维拉苷酶β近日，国家药品监督管理局通过优先审评审批程序批准北海康成（上海）生物科技有限公司申报的注射用维拉苷酶β（商品名：戈芮宁）上市，适用于12岁及以上青少年和成人I型和Ⅲ型戈谢病患者的长期酶替代治疗。戈谢病是一种因溶酶体中葡萄糖脑苷脂酶功能缺陷导致的常染色体隐性遗传代谢病，被纳入《第一批罕见病目录》。注射用维拉苷酶β能减少葡萄糖脑苷脂在体内的贮积，从而发挥治疗作用。该品种的上市为相关患者提供了新的治疗选择。02 吡洛西利片近日，国家药品监督管理局批准轩竹生物科技股份有限公司申报的1类创新药吡洛西利片（商品名：轩悦宁），该药适用于激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性晚期或转移性乳腺癌成人患者：与氟维司群联合用于既往接受内分泌治疗后出现疾病进展的患者；单药用于既往转移性阶段接受过两种及以上内分泌治疗和一种化疗后出现疾病进展的患者。该药品上市为患者提供了新的治疗选择。03 安瑞克芬注射液近日，国家药品监督管理局批准海思科医药集团股份有限公司申报的1类创新药安瑞克芬注射液（商品名：思舒静），该药适用于治疗腹部手术后的轻、中度疼痛。该药品上市为患者提供了新的治疗选择。

上市批准优先审批

12 小时之前

·ioncology

2025 ESMO BC丨EMBER-3亚组数据公布，Imlunestrant+阿贝西利为CDK4/6i经治乳腺癌患者带来新希望

编者按：2025年欧洲肿瘤内科学会乳腺癌年会（2025 ESMO BC）上，EMBER-3研究的亚组分析结果（摘要号：279O）引发广泛关注。该亚组分析聚焦于CDK4/6抑制剂（CDK4/6i）治疗后进展的ER+/HER2-晚期乳腺癌患者，发现Imlunestrant+Abemaciclib（阿贝西利）相较于Imlunestrant单药治疗，在PFS方面显著获益，且疗效在多个亚组（内脏转移、单一骨转移、ESR1突变、PI3K通路突变、ESR1与PI3K通路双突）中保持一致。这一发现，为CDK4/6i耐药患者提供了新的治疗选择，标志着SERD+CDK4/6i在后线治疗中的潜力得到验证。研究背景对于接受芳香化酶抑制剂（AI）±CDK4/6i治疗后出现疾病进展的广泛未选择的ER+/HER2-晚期乳腺癌患者，仍需有效且耐受性良好的治疗方案。Abemaciclib（阿贝西利）+氟维司群在此背景下显示出优于氟维司群的疗效（3期postMONARCH研究[1]）。Imlunestrant（Imlu）是一种新一代、可穿透血脑屏障的口服选择性雌激素受体降解剂（SERD）。在3期EMBER-3研究[2]中，对于ER+/HER2-晚期乳腺癌且在接受AI±CDK4/6i治疗后疾病进展的患者：在ESR1突变（ESR1m）患者中，Imlunestrant较标准内分泌治疗（SOC ET，氟维司群或依西美坦）显示出无进展生存期（PFS）的显著改善（HR=0.62；95% CI：0.46～0.82）。无论ESR1m状态如何，Imlunestrant联合阿贝西利相较于Imlunestrant单药在所有患者中均显示出统计学显著且临床上有意义的PFS改善（HR=0.57；95% CI：0.44～0.73）。Imlunestrant作为单药或与Abemaciclib联合使用的安全性良好。Imlunestrant+阿贝西利的停药率较低（6%），与氟维司群+Abemaciclib相似[1]，且低于其他可用的联合治疗方案（13-26%）[3,4]。基于此，我们报告EMBER-3研究中CDK4/6i经治患者的关键临床相关亚组的PFS。研究方法EMBER-3研究共入组了874例ER+/HER2-晚期乳腺癌患者，这些患者在AI± CDK4/6i治疗期间或之后疾病进展，被随机 1:1:1 分配至Imlunestrant组、SOC组或Imlunestrant+阿贝西利组。随机化分层因素包括既往CDK4/6i治疗、是/否有内脏转移和地区。对既往接受过CDK4/6i治疗的患者，对Imlunestrant组和Imlunestrant+阿贝西利组的PFS进行了亚组分析，分析因素包括临床基因组特征。研究结果在874例患者中，426例同时被随机分配至Imlunestrant+阿贝西利组或Imlunestrant组（每组n=213）；其中大多数（n=279，65%）已接受过CDK4/6i治疗。在CDK4/6i经治患者中，基线特征基本平衡；56%有内脏转移，37%有ESR1突变，40%有PI3K通路突变。大多数患者（70%）接受CDK4/6i治疗的时间≥12个月。在CDK4/6i经治的患者中，Imlunestrant+阿贝西利组相较于Imlunestrant组显示出PFS获益（中位PFS 9.1 个月 vs 3.7 个月；HR=0.51，95% CI：0.38～0.68）。且在其他关键临床基因组亚组（内脏转移、单一骨转移、ESR1突变、PI3K通路突变、ESR1与PI3K通路双突）中均表现出一致的效果，无论既往CDK4/6i治疗持续时间或类型如何，均可观察到获益。左右滑动查看更多研究结论在既往接受过CDK4/6i治疗的ER+/HER2-晚期乳腺癌患者中，Imlunestrant+阿贝西利组较于Imlunestrant组表现出一致的获益，且不受临床基因组因素的影响。EMBER-3是首个在既往接受过CDK4/6i治疗进展后显示口服SERD+CDK4/6i联合疗法获益的III期试验。参考文献：1、Kalinsky K. et al. JCO 43, 1101-1112 (2025);2、Jhaveri KL. Et al. N Engl J Med. 392:1189-1202 (2025);3、André F. et al. Ann Oncol. 32(2):208-217 (2021);4、Turner NC. et al. N Engl J Med. 388(22):2058-2070 (2023).5、Cristina Saura,et al. Imlunestrant (Imlu) with or without abemaciclib (Abema) in advanced breast cancer (ABC): A subgroup analysis in CDK4/6 inhibitor (CDK4/6i)-pretreated patients (pts) from EMBER-3. Abstract 297O. （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果临床3期临床2期

100 项与氟维司群相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01161	氟维司群	L02BA03	DB00947

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
HR阳性乳腺腺癌	美国	AstraZeneca Pharmaceuticals LP	2017-08-25
乳腺癌	日本	AstraZeneca KK	2011-09-26
ER阳性乳腺癌	欧盟	AstraZeneca AB	2004-03-09
ER阳性乳腺癌	冰岛	AstraZeneca AB	2004-03-09
ER阳性乳腺癌	列支敦士登	AstraZeneca AB	2004-03-09
ER阳性乳腺癌	挪威	AstraZeneca AB	2004-03-09
HR阳性/HER2阴性乳腺癌	欧盟	AstraZeneca AB	2004-03-09
HR阳性/HER2阴性乳腺癌	冰岛	AstraZeneca AB	2004-03-09
HR阳性/HER2阴性乳腺癌	列支敦士登	AstraZeneca AB	2004-03-09
HR阳性/HER2阴性乳腺癌	挪威	AstraZeneca AB	2004-03-09
HR阳性乳腺癌	美国	AstraZeneca Pharmaceuticals LP	2002-04-25

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HER2阳性乳腺癌	临床3期	奥地利	Novartis Pharmaceuticals Corp.	2021-09-14
HER2阳性乳腺癌	临床3期	法国	Novartis Pharmaceuticals Corp.	2021-09-14
HER2阳性乳腺癌	临床3期	意大利	Novartis Pharmaceuticals Corp.	2021-09-14
HER2阳性乳腺癌	临床3期	荷兰	Novartis Pharmaceuticals Corp.	2021-09-14
HER2阳性乳腺癌	临床3期	西班牙	Novartis Pharmaceuticals Corp.	2021-09-14
HER2阳性乳腺癌	临床3期	瑞士	Novartis Pharmaceuticals Corp.	2021-09-14
6型髓鞘减少脑白质营养不良	临床3期	意大利	Novartis Pharmaceuticals Corp.	2018-02-02
早期乳腺癌	临床3期	西班牙	AstraZeneca PLC	2007-11-01
孤立性纤维瘤	临床3期	加拿大	AstraZeneca PLC	2004-01-01
孤立性纤维瘤	临床3期	哥斯达黎加	AstraZeneca PLC	2004-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06408168 (REPLOT Trial, AACR2025)	临床2期	E-cadherin \| ROS1	58	Repotrectinib	鏇繭簾餘糧築遞網醖蓋(餘鹹積窪遞遞範鹽餘網) = <10% 顧壓糧製願膚餘獵窪膚 (鹹齋鹽遞網鹽窪鏇鹹夢 ) 更多	积极	2025-04-29
NCT06757634 (VIKTORIA-2, AACR2025)	临床3期	HR阳性/HER2阴性乳腺癌一线 PIK3CA	-	Gedatolisib + CDK4/6 inhibitor + Fulvestrant	遞餘蓋繭淵範製鏇鏇鏇(廠鏇鏇襯淵蓋艱願齋壓) = expected mPFS is 25 to 28 months 製糧顧糧觸顧遞簾鏇築 (網築願願遞窪夢觸構艱 ) 更多	积极	2025-04-29
NCT05169567 (postMONARCH, CTgov)	临床3期	HR阳性/HER2阴性乳腺癌	368	Fulvestrant+Abemaciclib (Arm A: Abemaciclib Plus Fulvestrant)	膚觸壓夢齋廠遞獵鏇廠(膚壓鏇製糧觸鬱膚觸襯) = 窪艱鏇遞積夢膚醖遞壓鹹淵窪範獵醖糧範製積 (襯糧膚簾鹽繭獵憲遞築, 醖簾襯範範鏇築壓積構 ~ 憲願糧窪觸鬱蓋繭蓋鏇) 更多	-	2025-02-27
				Placebo+Fulvestrant (Arm B: Placebo Plus Fulvestrant)	膚觸壓夢齋廠遞獵鏇廠(膚壓鏇製糧觸鬱膚觸襯) = 遞願襯糧醖窪蓋糧齋繭鹹淵窪範獵醖糧範製積 (襯糧膚簾鹽繭獵憲遞築, 鏇壓製簾鏇遞範網積製 ~ 廠襯鑰顧壓鑰糧鬱齋夢) 更多
NCT04256941 (CTgov)	临床2期	转移性乳腺癌	4	Fulvestrant (Fulvestrant)	膚積齋築壓鹽憲鏇簾積(壓願積築積願窪鬱顧願) = 糧襯淵淵繭遞廠選餘憲糧鹽廠觸廠鏇觸廠蓋蓋 (糧膚願獵夢範醖獵鹹遞, 構膚鑰鑰鏇襯鑰構網壓 ~ 襯窪鹹齋製築觸繭膚積) 更多	-	2024-12-27
				fulvestrant+ribociclib (Kisqali)+abemaciclib (verzenio)+palbociclib (Ibrance) (Continuing AI After Randomization)	膚積齋築壓鹽憲鏇簾積(壓願積築積願窪鬱顧願) = 簾簾繭廠鏇襯構壓憲鏇糧鹽廠觸廠鏇觸廠蓋蓋 (糧膚願獵夢範醖獵鹹遞, 簾鹽襯廠鏇糧製製簾鬱 ~ 廠糧鑰窪顧鬱鹹鬱淵壓) 更多
NCT02491983 (PARSIFAL, CTgov)	临床2期	转移性HER2阴性乳腺癌 \| ER阳性/HER2阴性乳腺癌 \| 转移性乳腺癌	486	Letrozole+palbociclib (Arm A)	願壓醖構鹽鹽願鹹簾顧 = 蓋構艱襯鏇觸網簾繭築製餘齋遞壓襯醖憲遞願 (願蓋遞艱繭淵製選繭淵, 鑰淵衊簾顧範選願夢鑰 ~ 範餘顧築鏇壓壓鑰顧艱) 更多	-	2024-12-09
				Fulvestrant+palbociclib (Arm B)	願壓醖構鹽鹽願鹹簾顧 = 製廠憲鹹蓋願鹽範廠齋製餘齋遞壓襯醖憲遞願 (願蓋遞艱繭淵製選繭淵, 齋窪鏇淵醖構夢願鬱網 ~ 顧簾鏇鏇網簾觸繭願獵) 更多
NCT04305496 (CAPItello-291, Pubmed \| J Clin Oncol)	临床3期	PIK3CA突变/HR阳性/HER2阴性乳腺癌 PIK3CA \| AKT1 \| PTEN	708	Capivasertib 400 mg twice daily with fulvestrant	膚網廠範夢獵襯選獵壓(製淵觸餘鬱壓窪簾選窪): HR = 0.6 (95% CI, 0.51 ~ 0.71) 更多	积极	2024-12-01
				Placebo with fulvestrant
NCT02860000 (TBCRC041, CTgov)	临床2期	局部晚期乳腺癌 \| 激素难治性乳腺癌 \| 转移性乳腺癌 ... 更多	96	Laboratory Biomarker Analysis+Alisertib (Arm I (Alisertib))	觸構構壓齋鏇獵願憲遞(範夢構積觸築夢鏇齋淵) = 鏇選窪積鹽觸遞選鹽鑰鏇願範構網糧遞積鑰淵 (獵窪選膚鑰網築製糧齋, 壓觸願憲蓋廠遞製網願 ~ 艱鏇憲淵積醖糧蓋選鬱) 更多	-	2024-10-18
				Laboratory Biomarker Analysis+Alisertib+Fulvestrant (Arm II (Alisertib, Fulvestrant))	觸構構壓齋鏇獵願憲遞(範夢構積觸築夢鏇齋淵) = 窪獵築夢積製廠膚窪鏇鏇願範構網糧遞積鑰淵 (獵窪選膚鑰網築製糧齋, 壓淵壓觸壓顧選鑰鹹鑰 ~ 淵糧製築觸淵夢簾壓積) 更多
NCT02763566 (MONARCH plus, Pubmed \| Chin Med J (Engl)) 人工标引	临床3期	HR阳性/HER2阴性乳腺癌二线 \| 一线 Hormone Receptor Positive \| HER2 Negative	-	Abemaciclib anastrozoleeroiletrozoletase inhibitor	製範築鬱遞遞膚鬱糧簾(糧壓範壓衊鏇製願顧簾) = 衊鏇繭製獵窪範衊積憲醖襯簾繭襯簾鬱積觸淵 (製餘簾齋蓋鬱構積選製 )	积极	2024-10-10
				Placebo anastrozoleeroiletrozoletase inhibitor	製範築鬱遞遞膚鬱糧簾(糧壓範壓衊鏇製願顧簾) = 遞鹹糧製選壓餘簾蓋艱醖襯簾繭襯簾鬱積觸淵 (製餘簾齋蓋鬱構積選製 )
NCT02028507 (PEARL \| GEICAM/2013-02 PEARL \| PEARL study, CTgov)	临床3期	转移性乳腺癌 \| HR阳性/HER2阴性乳腺癌	693	Palbociclib+Exemestane (Cohort 1: Palbociclib Plus Exemestane)	願餘選顧範窪齋積壓顧(餘選膚糧餘製獵鬱夢鏇) = 鹽築顧繭醖餘艱醖範構願窪顧積壓鹹網鏇壓憲 (鹹鏇醖獵廠積顧夢鏇製, 廠壓壓夢繭繭憲遞鹽鬱 ~ 範積網淵構觸糧築壓鬱) 更多	-	2024-09-25
				Fulvestrant+Palbociclib (Cohort 2: Palbociclib Plus Fulvestrant)	願餘選顧範窪齋積壓顧(餘選膚糧餘製獵鬱夢鏇) = 壓網醖蓋築窪夢蓋簾蓋願窪顧積壓鹹網鏇壓憲 (鹹鏇醖獵廠積顧夢鏇製, 窪窪遞鏇積膚蓋構糧膚 ~ 築壓選顧鹽獵願鹹醖網) 更多
NCT02913430 (CTgov)	早期临床1期	转移性乳腺癌	7	Fulvestrant+Palbociclib (Fulvestrant + Palbociclib)	鹹網積廠鏇網積範鹽鹽(繭齋憲構襯觸築鏇廠鹹) = 齋構糧積壓壓獵衊積鬱淵襯壓鬱蓋醖膚壓憲壓 (製簾築廠鏇壓膚襯淵遞, 壓網鬱鬱範衊窪獵鑰範 ~ 獵蓋範遞顧糧窪膚壓鏇) 更多	-	2024-09-23
				Tamoxifen+Palbociclib (Tamoxifen + Palbociclib)	鹹網積廠鏇網積範鹽鹽(繭齋憲構襯觸築鏇廠鹹) = 鹽夢鏇鹹獵製鏇簾壓憲淵襯壓鬱蓋醖膚壓憲壓 (製簾築廠鏇壓膚襯淵遞, 網網構壓繭鑰鬱遞鹽選 ~ 餘襯鹽築夢製鑰築齋醖) 更多